In a two-year study at UCLA, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC. Researchers led by Dr. Antoni Ribas found that the treatment’s side effects were manageable, and comparable to side effects for people who took either pembrolizumab or T-VEC as a standalone treatment.
UCLA scientists are testing the combination of pembrolizumab (marketed as Keytruda) and T-VEC (marketed as Imlygic) as a treatment option for people with advanced melanoma that doesn’t fully respond to either treatment separately.
Rendering of combination pembrolizumab (green form at top center) and T-VEC (green circles with red centers) in action. Credit: UCLA Jonsson Comprehensive Cancer Center
T-VEC is a genetically modified version of the herpes simplex virus that causes cold sores, but is safe to use. T-VEC has already been approved for the treatment of melanoma and it works both by directly killing cancer cells and using a protein that attracts immune cells into the cancers. Pembrolizumab has become a standard-of-care treatment for advanced melanoma, and it is also being used to treat non–small-cell lung cancer, cancers of the head, neck, kidney and bladder, and Hodgkin’s disease. It works by taking the “brakes” off of the body’s immune system, enabling it to attack cancer.
According to Ribas, people whose melanoma does not respond to pembrolizumab often lack a type of T cell called CD8+ in their tumors; the lack of CD8+ cells seems to prevent immunotherapy drugs from working. But the researchers believe those people might benefit from a combination therapy, because T-VEC attracts CD8+ immune cells to the tumors and pembrolizumab allows them to attack the cancer cells.
The phase 1 clinical trial evaluated 21 people with advanced melanoma. Researchers injected patients’ melanoma tumors with T-VEC for six weeks and then gave them infusions of pembrolizumab. Sixty-two percent of the patients had a partial or complete response, meaning that their tumors either shrank or were no longer detectable.
The combination therapy could provide an alternative treatment for people with melanoma whose tumors don’t respond to other therapies. It is also being tested in people with head, neck and colon cancers.
Source: UCLA